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Abstract Creatine has become one of the most popular
dietary supplements in the sports nutrition market. The
form of creatine that has been most extensively studied and
commonly used in dietary supplements is creatine mono-
hydrate (CM). Studies have consistently indicated that
CM supplementation increases muscle creatine and phos-
phocreatine concentrations by approximately 15–40%,
enhances anaerobic exercise capacity, and increases train-
ing volume leading to greater gains in strength, power, and
muscle mass. A number of potential therapeutic beneﬁts
have also been suggested in various clinical populations.
Studies have indicated that CM is not degraded during
normal digestion and that nearly 99% of orally ingested
CM is either taken up by muscle or excreted in urine.
Further, no medically signiﬁcant side effects have been
reported in literature. Nevertheless, supplement manufac-
turers have continually introduced newer forms of creatine
into the marketplace. These newer forms have been pur-
ported to have better physical and chemical properties,
bioavailability, efﬁcacy, and/or safety proﬁles than CM.
However, there is little to no evidence that any of the newer
forms of creatine are more effective and/or safer than CM
whether ingested alone and/or in combination with other
nutrients. In addition, whereas the safety, efﬁcacy, and
regulatory status of CM is clearly deﬁned in almost all
global markets; the safety, efﬁcacy, and regulatory status of
other forms of creatine present in today’s marketplace as a
dietary or food supplement is less clear.
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Introduction
Creatine (N-(aminoiminomethyl)-N-methyl glycine) is an
ingredient commonly found in food, mainly in ﬁsh and
meat, and is sold as a dietary supplement in markets around
the world. Its use as an ergogenic aid and possible treat-
ment for certain neuromuscular disorders is well
documented in scientiﬁc literature (Buford et al. 2007;
Kreider et al. 2010). In recent years, the popularity of
creatine has risen dramatically, especially among athletes.
In the USA alone, creatine-containing dietary supplements
make up a large portion of the estimated $2.7 billion in
annual sales of sports nutrition supplements (NBJ 2009).
Accompanying this explosive growth in sales has been
the introduction of different forms of creatine. Creatine
monohydrate (CM), ﬁrst marketed in the early 1990s, is the
form most commonly found in dietary supplement/food
products and most frequently cited in scientiﬁc literature.
The introduction into the marketplace of alternate forms of
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DOI 10.1007/s00726-011-0874-6creatine, beginning in the late 1990s, was presumably an
attempt to differentiate the multitude of creatine-containing
products available to consumers and improve certain
attributes such as solubility and efﬁcacy. However, the
legal and regulatory status of these various forms of crea-
tine in the USA and other markets around the world is at
best uncertain. To date, with the exception of Japan, CM is
the only form of creatine to be ofﬁcially approved or
accepted in key markets such as the USA, European Union
(EU), Canada and South Korea. The continued presence of
other forms of creatine in the marketplace, especially in the
US, may be due to a multitude of factors. These include,
but may not be limited to, a lack of awareness or under-
standing on the part of marketers of applicable laws and
regulations, intentional noncompliance with the law, and/or
inadequate enforcement of the law. The public health
implications of widespread distribution and use of these
unauthorized forms of creatine is unknown and warrants
careful monitoring.
New forms of creatine are marketed with claims of
improved physical, chemical, and physiological properties
in comparison to CM. Claims include improved stability
when combined with other ingredients or in liquids,
improved solubility in water, improved bioavailability, and
even an increase in performance. This review will evaluate
the available literature on new forms of creatine and
compare them to available data on CM in terms of efﬁcacy
and safety. In addition, the current international regulatory
status of the various forms of creatine that are commer-
cially available will be examined.
Methods
This analysis represents a systematic review of the litera-
ture on the various forms of creatine available in the global
marketplace as dietary supplements, food supplements, or
natural health products. For technical and performance
comparisons, literature searches were performed by
searching the Medline database of the US National Library
of Medicine of the National Institutes of Health. The search
strategy involved entering the various creatine search terms
(Table 1), along with the technical or performance aspect
of interest (e.g., solubility, stability, bioavailability, per-
formance). In addition, a patent research was performed by
searching the database of the World Intellectual Property
Organization (WIPO), the European Patent Ofﬁce, the
Japan Patent Ofﬁce, and the United States Patent and
Trademark Ofﬁce. Articles were reviewed, analyzed, and
interpreted, with results of the relevant studies presented
below.
For the assessment of the current regulatory status of the
various forms of creatine, the Web sites of regulatory
bodies for key markets around the world were accessed
(USA: US Food and Drug Administration; Canada: Health
Canada; EU: European Commission; Japan: Ministry of
Health, Labor and Welfare; Korea: Korea Food and Drug
Administration). Information derived from these sites was
used to determine the legal and regulatory framework
governing creatine products in these markets and the cur-
rent regulatory status of the various forms of creatine as
dietary supplements, food supplements, and natural health
products.
Physio-chemical properties
Creatine crystallizes from water as monoclinic prisms
holding one molecule of water of crystallization per mol-
ecule of creatine. Continued drying of CM results in a loss
of the water of crystallization at around 100°C, yielding
anhydrous creatine. Creatine is a weak base with a pkb
value of 11.02 at 25°C. As a result, creatine can only form
salts with strong acids, having a pka value of less than 3.98.
Creatine forms salts by the protonation of its guanidine
moiety (see Fig. 1). In addition to salt formation, creatine is
able to act as a complexing agent.
Creatine salts such as citrate, maleate, fumarate, tartrate
(Negrisoli and Del Corona 1997), pyruvate (Pischel and
Weiss 1996), ascorbate (Pischel et al. 1999), and orotate
(Abraham and Jiang 2005) were ﬁrst introduced to the
marketplace as early as the late 1990s. Creatine and acids
Table 1 Creatine content of different forms of creatine
Form of creatine Creatine
content (%)
Difference
in CM (%)
Creatine anhydrous 100.0 +13.8
CM 87.9 0
Creatine ethyl ester 82.4 −6.3
Creatine malate (3:1) 74.7 −15.0
Creatine methyl ester HCl 72.2 −17.9
Creatine citrate (3:1) 66 −24.9
Creatine malate (2:1) 66 −24.9
Creatine pyruvate 60 −31.7
Creatine α-amino butyrate 56.2 −36.0
Creatine α-ketoglutarate 53.8 −38.8
Sodium creatine phosphate 51.4 −41.5
Creatine taurinate 51.4 −41.6
Creatine pyroglutamate 50.6 −42.4
Creatine ketoisocaproate 50.4 −42.7
Creatine orotate (3:1) 45.8 −47.9
Carnitine creatinate 44.9 −49.0
Creatine decanoate 43.4 −50.7
Creatine gluconate 40.2 −54.3
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123with multiple acid moieties such as citric acid can form
salts as well as complexation products. The ﬁrst acid
moiety of citric acid is strong enough (pka = 3.09) to form
a salt with creatine; however, the other two moieties
(pka2 = 4.75, pka3 = 5.41) should only be able to form
complexes with creatine. A salt, a salt-complex combina-
tion, or a simple physical mixture can be differentiated by
measurement of the enthalpy changes of neutralization,
which ranges usually in the area of −55 to −66 kJ/mole for
the salt formation to less than −5 kJ/mole for the change in
complexation enthalpy to no changes in enthalpy for a
physical mixture (1995). A “tricreatine citrate” is actually a
complex of creatine citrate with two additional creatine
moieties, resulting in a molecule with a ratio of creatine to
citrate of 3:1.
In addition to creatine and its salts, derivatives of cre-
atine such as creatine ester or even creatine alcohols are
currently marketed as dietary supplements in the USA (see
Fig. 2). Both ingredients do not contain creatine as such,
since they have been chemically altered. While it is
assumed that the human body will transfer those molecules
into creatine upon intake, there are no published data
available to base ﬁrm conclusions.
The amount of creatine in different forms of creatine
varies. Creatine monohydrate contains 87.9% of creatine,
whereas the creatine content in other forms of creatine is
lower with the exception of creatine anhydrous (see
Table 1). Commercial creatine salts are formed in solution
or by mechanical processes such as milling or grinding
under the presence of residual water. Complexes are
formed by the subsequent replacement of the solvating
molecules by the new ligands.
Solubility
One major limitation of creatine as an ampholytic amino
acid is its rather low solubility in water. The solubility of
creatine in water increases with temperature and the
correlation between solubility and temperature is almost
linear. One liter of water dissolves 6 g of creatine at 4°C,
14 g at 20°C, 34 g at 50°C, and 45 g at 60°C. The solubility
of creatine can also be increased by lowering the pH of the
solution. This principle is the basis for the improved sol-
ubility of creatine salts, since creatine salts lower the pH of
water due to the nature of acid moiety. Creatine monohy-
drate dissolves at 14 g/L at 20°C resulting in a neutral pH
of 7. A saturated solution of tricreatine citrate in water has
a pH of 3.2; whereas a saturated solution of creatine
pyruvate even has a pH of 2.6 (pyruvic acid is a stronger
acid than citric acid). The decrease in pH results in an
increase in solubility: 29 g/L creatine citrate at 20°C, and
54 g/L creatine pyruvate at 20°C. Normalized by the rel-
ative amount of creatine per molecule (monohydrate
87.9%, citrate 66%, pyruvate 60%), creatine citrate
(19.14 g/L) shows a 1.55-fold and creatine pyruvate
(32.4 g/L) a 2.63-fold better solubility when compared with
the monohydrate (12.3 g/L). Whereas the creatine deriva-
tive creatinol-O-phosphate (5 g/L at 20°C) has inferior
solubility, dicreatinol sulfate (1,370 g/L at 20°C) shows
superior solubility when compared with CM, creatine salts,
or creatine esters (Godfraind et al. 1983; Gastner et al.
2005).
Stability
Stability in solid form
Creatine monohydrate powder is very stable showing no
signs of degradation over years, even at elevated temper-
atures. To detect a potential degradation of creatine, one
must measure the content of its degradation product, cre-
atinine (see Fig. 3), which can be quantiﬁed by HPLC at
levels as low as 67 parts per million (ppm). At room
temperature and even at an increased temperature of 40°C
(104°F), CM shows no signs of degradation (i.e., creatinine
levels stay under the quantiﬁcation limit of 67 ppm) after
more than 3 years. As Fig. 3 shows, even when stored at
60°C (140°F), creatinine (106 ppm) was only detected after
a period of 44 months (Ja ¨ger 2003).
Stability in solutions
As shown in Fig. 4, in contrast to its stability in a solid
state, creatine is not stable in aqueous solution due to an
+
Creatine Strong Acid Creatine-Salt
NH2
N H2N
CH3
O
O
NH2
N H2N
CH3
O
OH
HA A
H2O
Fig. 1 Creatine salts
Creatine Creatine Ethylester
NH2
N H2N
CH3
O
O
NH
N H2N
CH3
O
O
CH3
Creatinol-O-Phosphate
NH
N H2N
CH3
OP
O
OH
OH
Fig. 2 Chemical structure of
creatine and creatine derivatives
Efﬁcacy and safety of novel creatine forms 1371
123intramolecular cyclization (Howard and Harris 1999). The
rate of creatine degradation in solution is not dependent on
its concentration, but on pH. Generally, the lower the pH
and higher the temperature, the faster is the degradation.
This solid-state and degradation properties have been
thoroughly investigated as early as the 1920s (Edgar and
Shiver 1925; Cannon et al. 1990) and more recently by
Dash et al. (2002), as well as Harris et al. (Howard and
Harris 1999). These researchers found that whereas crea-
tine was relatively stable in solution at neutral pH (7.5 or
6.5), a lowering of pH resulted in an increased rate of
degradation and after only 3 days of storage at 25°C cre-
atine degraded signiﬁcantly: 4% at pH 5.5; 12% at pH 4.5;
and 21% at pH 3.5 (see Fig. 5). Similarly, Ganguly et al.
(2003) reported that creatine monohydrate stored at room
temperature degraded into creatinine within several days
but that refrigerating creatine monohydrate in solution
slowed degradation. The rapid degradation of creatine in
solution precludes the manufacture of shelf-stable standard
acidic beverages containing efﬁcacious amounts of the
ingredient. If creatine is not consumed immediately after it
has been dissolved in water, it should be stored at a low
temperature to retard the degradation.
The degradation of creatine can be reduced or even
halted by either lowering the pH under 2.5 or increasing the
pH. A very high pH results in the deprotonation of the acid
group, thereby slowing down the degradation process by
making it more difﬁcult for the intramolecular cyclization.
A very low pH results in the protonation of the amide
function of the creatine molecule, thereby preventing the
intramolecular cyclization (see Fig. 6). This effect also
occurs under the acidic conditions in the stomach, hence
preventing the breakdown of creatine. The conversion of
creatine to creatinine in the gastrointestinal tract is minimal
regardless of transit time (Persky et al. 2003; Harris et al.
1992b; Deldicque et al. 2008).
Stability of other forms of creatine
Some creatine salts appear to be less stable when compared
with CM. Tricreatine citrate results in creatinine levels of
770 ppm at 40°C (104°F) after 28 days of storage. How-
ever, the addition of carbohydrates has been shown to
increase stability of some creatine salts (Purpura et al.
2005). Creatine salts are not expected to have a greater
stability in solution; however, the pH lowering effect of the
salt might reduce stability compared to CM in the same
environment.
Tallon et al. (Child and Tallon 2007) compared the
stability of creatine ethyl ester (CEE) head to head with
CM and found that CEE was actually less stable than CM.
It was concluded that the addition of the ethyl group to
creatine actually reduced acid stability and accelerated its
breakdown to creatinine. The degradation of creatine and
Fig. 3 Stability of creatine monohydrate powder. Adapted from Ja ¨ger
(2003)
N
H3C
HN
NH2
OH
O
- H2O
N
H
N
H3C
HN O
Creatine Creatinine
+ H2O
Fig. 4 Degradation of creatine to creatinine
Fig. 5 Effect of pH on creatine stability in solution. Adapted from
Howard and Harris (1999)
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123creatine ester involves intramolecular hydrolysis of a car-
boxyl acid (in case of creatine) or carboxylic ester (in case
of creatine methyl- or ethyl ester) under acidic conditions
and the rate of degradation depends on the leaving group
(see Fig. 7). It is speculated that the methyl ester or ethyl
ester groups are better leaving groups than hydroxyl or
water and, therefore, suggesting that the degradation into
creatinine should be rather accelerated.
These ﬁndings are also in accordance with the recent
investigations on the stability of CEE at 37ºC in both water
and phosphate-buffered saline and the in vitro response of
CEE to incubation in human plasma by H-NMR analysis
(Giese and Lecher 2009b). The conversion of CEE to
creatine by the esterases in human plasma was not detec-
ted, and the only species detected after the incubation
period was creatinine. It is concluded that CEE is mostly
converted into creatinine under physiological conditions
encountered during transit through the various tissues,
suggesting no ergogenic effect is to be expected from
supplementation of CEE. The high stability of CM is well
documented, whereas the stability of newer forms of cre-
atine (salts, ester, etc.) either has not been investigated or
appears to be inferior. New forms of creatine contain less
of the active principal creatine in comparison to CM;
however, creatine salts can offer an advantage over CM
with regard to solubility.
Bioavailability
The uptake of creatine is simpliﬁed in a two-step approach:
ﬁrst, uptake into the blood stream; second, uptake into the
target tissue. The term ‘bioavailability’ refers to both the
intestinal absorption and the use of a substance by the
body’s cells and tissues. First indications of a potential
change of creatine bioavailability can be gathered from the
amount of creatine taken up into the blood plasma after
oral administration. However, a change in the total amount
of creatine in the blood plasma cannot be directly extrap-
olated to a potential increase in desired performance. An
increased amount of creatine in the plasma could be the
result of decreased uptake into the target tissue resulting in
an actual decrease in overall bioavailability. On the other
hand, an initial rise in plasma creatine levels, followed by a
reduction in plasma levels, is an indication of increased
uptake into the target tissue. This has been demonstrated in
vivo by combining creatine with insulin-stimulating
ingredients such as high amounts of glucose or protein
(Bessman and Mohan 1992; Haughland and Chang 1975;
Rooney et al. 2002). Conclusive proof of an increase in
relevant bioavailability can only be gained by assessing the
amount of creatine reaching the target tissue, the muscle,
measured by muscle biopsy and/or whole body creatine
retention assessed by measuring the difference between
creatine intake and urinary excretion.
Dietary creatine is presumed to have high bioavailability
since intestinal absorption of CM is already close to 100%
(Deldicque et al. 2008). However, the response to creatine
supplementation is heterogeneous, due in part to some non-
responders, which might be overcome by alternative forms
of creatine (Greenhaff 1997b; Greenhaff et al. 1993).
Several studies have examined whether different forms of
creatine are more effective in terms of promoting muscle
uptake of creatine than CM. For example, a recent study
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123examined the effect of the administration of three different
forms of creatine on plasma creatine concentrations and
pharmacokinetics. In a balanced cross-over designed study,
six healthy subjects were assigned to ingest a single dose of
isomolar amounts of creatine (4.4 g) in the form of CM,
tricreatine citrate (TCC), or creatine pyruvate (CPY), fol-
lowed by measurement of the plasma creatine levels (Ja ¨ger
et al. 2007). Mean peak concentrations and area under the
curve (AUC) were signiﬁcantly higher with CPY (17 and
14%, respectively) in comparison to CM. The ﬁndings
suggest that different forms of creatine may result in
slightly different kinetics of plasma creatine absorption,
although differences in velocity constants of absorption
could not be detected due to the small number of blood
samples taken during the absorption phase. The small
differences in kinetics are unlikely to have any clinically
relevant effects on muscle creatine elevation during periods
of creatine loading. A follow-up study including muscle
biopsies would be required to conclude if the bioavail-
ability of this speciﬁc creatine salt was indeed higher
(Fig. 8).
Greenwood et al. (2003) investigated how different
forms of creatine affect whole body creatine retention.
Sixteen males were assigned to ingest in a single blind
manner either 5 g of dextrose, 5 g of CM, 5 g of CM plus
18 g dextrose, or an effervescent creatine supplement
consisting of 5 g of TCC (66% creatine) plus 18 g dextrose
four times/day for 3 days. Creatine retention was estimated
by subtracting total urinary creatine excretion from total
supplemental creatine intake over the 3-day period. Results
revealed that average daily creatine retention over the
3-day period was 12.2 ± 1.3, 16.1 ± 2.2, and 12.6 ± 2.5 g/
day for the CM, CM with dextrose, and effervescent TCC
groups, respectively. This amounted to whole body crea-
tine retention of 61 ± 15% for the CM group, 80 ± 11%
for the CM plus dextrose group, and 63 ± 13% for the
effervescent TCC group. While creatine retention was
signiﬁcantly greater in the CM and dextrose group, no
signiﬁcant differences were seen between the CM and
effervescent TCC groups. These ﬁndings suggest that while
consuming a relatively small amount of dextrose with CM
can increase whole body creatine retention, supplementa-
tion of TCC in an effervescent form does not augment
whole body creatine retention more than CM alone (Fig. 9).
Over the years, there has been signiﬁcant commercial
interest in determining whether creatine could be delivered
in a liquid form. The thought has been since CM is rela-
tively insoluble that development of a liquid or suspended
form of creatine may be more convenient to consume, be
more readily absorbed into the blood stream, and promote a
greater efﬁciency in transport of creatine to the muscle.
Some companies have even claimed that minimal amounts
of liquid creatine would need to be ingested because of
enhanced efﬁciency in transport through the blood and into
the muscle. A limitation with these theories is that CM is
not stable for any substantial length of time in liquid.
Consequently, while researchers have been working on
ways to suspend creatine within gels and ﬂuids, it has been
generally considered to be impractical to develop into a
product due to limitations in shelf-life. In addition, while
people may prefer the taste of liquid or gel versions of
creatine, there is no evidence that these delivery forms
provide a superior performance beneﬁt.
Kreider et al. (2003b) carefully compared the effects
of ingesting 20 g/day of CM to recommended doses
0
200
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600
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1000
Plasma creatine
µmol/l
0 2468
Time (h)
7.3g CYP
6.7g CC
5g CM
Fig. 8 Comparison of blood plasma levels of different forms of
creatine. Adapted from Ja ¨ger et al. (2007)
Fig. 9 Percentage of creatine retained during a 3-day loading period
(20 g/day). Adapted from Greenwood et al. (2003)
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123(2.5 g/day of CM), as well as doses that would purportedly
provide an equivalent amount of CM per day in liquid form
(20 g/day) on muscle creatine, phosphocreatine, and total
creatine levels. Subjects donated muscle biopsies prior to
and following 5 days of supplementing their diet in a
randomized and double-blind manner with either 5 mL of
creatine liquid (purportedly providing 2.5 g of CM), 5 mL
of a ﬂavored placebo, 8 9 5 mL doses of creatine liquid
(purportedly providing 20 g/day of CM), or 8 9 5m L
doses of a ﬂavored placebo. Another group ingested
4 9 5 g of CM for 5 days as a non-blinded benchmark
control. This analysis allowed for a comparison of ingest-
ing recommended doses of liquid creatine to a placebo, as
well as seven times the amount recommended by the
manufacturer that would purportedly provide an equal
amount of CM. The researchers found that CM supple-
mentation signiﬁcantly increased muscle free creatine
content by 31 ± 28%. However, none of the other groups
experienced any effect on muscle free creatine, phospho-
creatine, or total creatine content. Moreover, changes in
muscle creatine and phosphocreatine levels in response to
CM supplementation were signiﬁcantly greater than the
liquid creatine and placebo groups. These ﬁndings indicate
that liquid creatine supplementation has no effect on
muscle phosphagen levels and therefore may have no
ergogenic value. While other groups have been attempting
to develop stable forms of liquid and/or gel forms of cre-
atine with some success, there are no data available to date
demonstrating that these types of creatine are absorbed
more efﬁciently and/or have greater beneﬁt compared to
CM (Fig. 10).
An alternative dissolved form of creatine is colloidal
CM. CM is dissolved in its own crystal water and dispersed
into a stable protective matrix containing carbohydrates
(Kessel et al. 2004). The product is claimed to be the only
solubilized form of powdered creatine in the market,
making it more bioavailable and stable. However, no evi-
dence has been published to date to substantiate any
performance or ergogenic beneﬁt from this form of
creatine.
Creatine ethyl ester has been purported to be a superior
form of creatine in comparison to CM. However, prior
studies have shown that it degrades rather quickly to cre-
atinine when exposed to low pH levels as would be found
in the stomach (Giese and Lecher 2009a; Katseres et al.
2009). Theoretically, this would reduce the bioavailability
of creatine. To test this hypothesis, Spillane et al. (2009)
compared the effects of supplementing the diet with a
placebo, CM, or CEE during 42 days of training. Serum
creatinine and muscle total creatine content was assessed
prior to and following 6, 27, and 48 days of supplemen-
tation and training. The researchers found that serum
creatinine levels were signiﬁcantly increased in the CEE
group after 6, 27, and 48 days of supplementation indi-
cating less efﬁcient bioavailability. In addition, while CEE
supplementation promoted a modest increase in muscle
total creatine content, it was increased to a greater extent in
the CM group. These ﬁndings directly contradict claims
that CEE is more effective in increasing muscle creatine
stores. Further, the signiﬁcantly higher creatinine levels
observed should raise some potential safety concerns about
potential safety (Fig. 11).
Several studies have also evaluated whether co-inges-
tion of creatine with other nutrients may inﬂuence creatine
retention. Initial work by Green and colleagues (Green
et al. 1996a, b) demonstrated that co-ingesting creatine
(5 g) with large amounts of glucose (e.g., 95 g) enhanced
creatine and carbohydrate storage in muscle. Subsequent
studies by Steenge et al. (2000) found ingesting creatine
(5 g) with 47–97 g of carbohydrate and 50 g of protein also
enhanced creatine retention. The researchers suggested that
Fig. 10 Change in muscle-free creatine content in response to 5 days
of low or high-dose creatine serum and placebo ingestion compared to
CM. Adapted from Kreider et al. (2003b)
Fig. 11 Changes in total muscle creatine content in response to
placebo (PLA), creatine monohydrate (CRT), and creatine ethyl ester
(CEE) supplementation (Spillane et al. 2009).
†Signiﬁcantly different
from PLA group. *Signiﬁcant difference from baseline. Reprinted
with permission
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123creatine transport was mediated in part by glucose and
insulin. As a result, additional research has been under-
taken to assess the effect of co-ingesting creatine with
nutrients that may enhance insulin sensitivity on creatine
retention.
Several studies have examined whether co-ingesting
creatine with D-pinitol inﬂuences whole body creatine
retention. In the ﬁrst study (Greenwood et al. 2001), 12
male subjects with no history of creatine supplementation
donated 24-h urine samples for 4 days. After an initial
control day designed to determine normal daily creatine
excretion rates, subjects were then matched according to
body mass and randomly assigned to ingest in a single-
blind manner either a placebo (4 9 5 g doses of dextrose),
CM (4 9 5 g), CM with low-dose D-pinitol (4 9 5gC M
with 2 9 0.5 g of D-pinitol), or CM with high-dose D-pinitol
(4 9 5 g CM with 4 9 0.5 g D-pinitol) for 3 days. Whole
body creatine retention was estimated by subtracting total
urinary creatine excretion from total supplemental creatine
intake over the 3-day period. Results revealed that whole
body creatine retention over the 3-day loading period was
signiﬁcantly greater in the low-dose D-Pinitol group in
comparison to the group ingesting CM alone. However, no
differences were seen between CM alone and CM with the
higher dose of D-Pinitol (Fig. 12).
In a follow-up study, Kerksick et al. (2009) examined
whether co-ingestion of D-pinitol with CM would affect
training adaptations, body composition, and/or whole-body
creatine retention in resistance-trained males. In the study,
24 resistance trained males were randomly assigned in a
double-blind manner to CM + D-pinitol or CM alone prior
to beginning a supervised 4-week resistance training pro-
gram. Subjects ingested a typical loading phase (i.e., 20 g/
day for 5 days) before ingesting 5 g/day for the remaining
23 days. Results revealed that creatine retention increased
in both groups as a result of supplementation. However, no
signiﬁcant differences were observed between groups in
training adaptations. Consequently, additional research is
needed to determine whether D-pinitol supplementation
enhances creatine uptake and/or affects the ergogenicity of
creatine supplementation before ﬁrm conclusions can be
drawn.
Russian tarragon (Artemisia dracunculus) is an etha-
nolic extract that is often used as a cooking herb. Studies
have shown that Russian tarragon (RT) appears to have
antihyperglycemic activity when combined with CM
ingestion (Ja ¨ger et al. 2008a; Wang et al. 2008). Theoret-
ically, ingesting RT extract prior to creatine loading may
enhance insulin sensitivity and thereby promote greater
creatine absorption/retention. To support this hypothesis,
Ja ¨ger et al. (2008a) reported that RT inﬂuences plasma
creatine levels during the ingestion of CM in a similar
manner to glucose and protein. However, further research
is needed to evaluate the effects of RT on creatine uptake
and retention in muscle before conclusions can be drawn
(Fig. 13).
In analysis of this literature, it is clear that CM sup-
plementation promotes signiﬁcant increases in muscle
creatine levels in most individuals. There is some evidence
that co-ingestion of CM with various nutrients (e.g., car-
bohydrate, protein, D-pinitol) may enhance creatine uptake
to a greater degree. However, there is no evidence that
effervescent creatine, liquid creatine, and/or CEE promotes
greater uptake of creatine to the muscle. Rather, there is
some evidence that some of these forms of creatine may be
less effective and/or be of greater clinical concern in terms
of safety.
Fig. 12 Change in whole body creatine retention in response to
5 days of placebo, creatine monohydrate (CM), low-dose D-pinitol (P)
and CM, and high-dose P and CM supplementation. Adapted from
Kerksick et al. (2007)
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Fig. 13 Inﬂuence of Russian tarragon on creatine absorption.
Adapted from Ja ¨ger et al. (2008a)
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Creatine monohydrate
Numerous studies have found that CM supplementation
increases muscle phosphagen levels generally by 10–40%
(Greenhaff 1997a; Harris et al. 1992a; Hultman et al.
1996). Acute and chronic supplementation of CM has been
reported to improve performance primarily during high
intensity, intermittent activities (Greenhaff 1997a; Kraemer
and Volek 1999; Kreider 2003). The impact on perfor-
mance has been associated with the magnitude of change in
baseline phosphagen levels (Burke et al. 2003a; Greenhaff
1997a). Numerous studies have shown that CM supple-
mentation during training promotes greater gains in
performance and/or fat-free mass (Cribb and Hayes 2006;
Kreider et al. 1998; Volek et al. 1997, 1999; Willoughby
and Rosene 2001; Willoughby and Rosene 2003). The only
clinically signiﬁcant side effect reported in literature has
been weight gain, which is an attribute desired by many
athletes who desire to increase muscle mass as well as
clinical populations concerned about muscle wasting
(Bender et al. 2008; Dalbo et al. 2008; Kreider et al. 2003a;
Schilling et al. 2001). Consequently, CM has proven to be
one of the most effective, safe, and well-studied ergogenic
aids.
Creatine salts
Creatine has been combined with different organic acids to
form creatine salts with the intention of using acids that
will create a synergistic effect or simply improve the
properties of creatine. A limitation of this approach is that
effective daily doses of creatine and the acid will have to
match to achieve meaningful physiological effects. In
addition, creatine salts will have to outperform the physical
mixture of CM and the corresponding acid, showing syn-
ergistic effects.
Inorganic salts of pyruvic acid have been shown to
improve endurance when ingested in high amounts in rats
(Ivy 1998), and consequently creatine has been combined
with pyruvic acid to form creatine pyruvate (CPY), with
the suggested beneﬁt of a synergistic effect between the
two. The potential endurance enhancing effects of CPY has
been investigated in several studies, using doses of pyru-
vate signiﬁcantly lower than previously found to be
effective. Two studies investigating the endurance exercise
capacity of short-term CPY supplementation showed
mixed results. In this regard, 7 days of 7 g per day CPY
supplementation did not beneﬁcially impact endurance
capacity or intermittent sprint performance in well-trained
cyclists (Van Schuylenbergh et al. 2003), whereas 5 days
of 7.5 g per day CPY intake increased paddling speed and
resulted in decreased lactate concentrations in Olympic
canoeists, suggesting an increase in aerobic metabolism
(Nuuttilla 2000). A recent double-blind, placebo-con-
trolled, randomized study evaluated the effect of oral CPY
supplementation on exercise performance in healthy young
athletes in comparison to placebo and TCC (Ja ¨ger et al.
2008b). It was concluded that 4 weeks of supplementation
with creatine salts signiﬁcantly improved performance
during intermittent handgrip exercise of maximal intensity
and that CPY might beneﬁt endurance, due to enhanced
aerobic metabolism. This study is a ﬁrst indication that the
creatine salt CPY may have potential advantage over CM.
However, more research is needed to investigate this effect.
Creatine citrate (CC) has been used in several perfor-
mance studies; however, none of those studies compared
the product to CM. High-dose, short-term CC supplemen-
tation (4 9 5 g CC per day for 5 days) has been found to
increase anaerobic working capacity (AWC) in healthy
physically active women (Eckerson et al. 2004) and is able
to delay the onset of neuromuscular fatigue during cycle
ergometry (Smith et al. 2007). In a recent study, CC sup-
plementation was able to raise the ventilatory threshold
during intensity interval training (Graef et al. 2009).
Although these studies are interesting, more research is
needed particularly comparing CC to CM before it can be
concluded that CC has any additional beneﬁts.
Creatine ester
To date, Spillane et al. (2009) are the only group that has
studied the impact of CEE supplementation on training
adaptations in resistance trained individuals. The
researchers randomly assigned in a double-blind manner 30
male resistance-trained athletes to ingest 0.30 g/kg per day
fat-free mass (about 20 g/day) of either a placebo, CM, or
CEE for 42 days. As stated previously, CEE supplemen-
tation did not promote greater total muscle creatine levels
in comparison to placebo. In terms of training adaptations,
CEE supplementation did not promote greater gains in
body mass, fat-free mass, strength, or sprint performance.
These ﬁndings indicate that CEE has no apparent ergogenic
value over CM despite widespread claims that it is a more
superior form of creatine. Additionally, the signiﬁcantly
higher creatinine levels observed indicate it is degraded to
a greater degree and may pose greater safety concerns.
Creatinol
Creatinol in the form of creatinol-O-phosphate (COP) has
been described and used in subjects with deﬁcient myo-
cardial circulation (Guglielmi and Mammarella 1979).
Based on the ﬁndings that intravenous administration of
COP in healthy human subjects led to increased values of
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precursor of creatine and is metabolized into creatine
within the body (Melloni et al. 1979). The increased uri-
nary values are derived from the degradation of creatine
into creatinine through the typical biochemical pathways.
Only one study investigated the ability of COP to improve
muscular performance (Nicaise 1975). Fifty female
patients were treated intramuscularly and intravenously
with COP and performance tested utilizing a Martin Vig-
orimeter to measure muscle strength in both hands. The
administration of COP resulted in a statistically signiﬁcant
improvement in hand strength.
Creatine-containing nutritional formulations
Since a number of studies have reported that CM supple-
mentation can increase performance and/or training
adaptations, there has been interest in determining whether
ingesting creatine with other potentially ergogenic nutri-
ents may affect performance and/or training adaptations to
a greater degree. For example, studies have indicated that
ingesting creatine with vitamin and mineral-fortiﬁed car-
bohydrate and protein supplements promote greater gains
in strength and fat-free mass than carbohydrate or carbo-
hydrate and protein supplements alone (Kreider et al. 1996,
1999; Cribb et al. 2007a; Kreider et al. 1998). Additionally,
co-ingesting creatine with different types of protein may
have differential effects on gains in fat-free mass and/or
training adaptations (Kerksick et al. 2007; Cribb et al.
2007b). Several studies have also indicated that co-
ingesting CM with other potentially ergogenic nutrients
such as beta-hydroxy-beta-methylbutyrate (HMB) (Jowko
et al. 2001), beta-alanine (Hoffman et al. 2006), phosphates
(Eckerson et al. 2005), and alpha-lipoic acid (Burke et al.
2003b) may have some additive effects. While not all
studies have reported statistically signiﬁcant differences,
these studies and others support contentions that including
CM in nutritional formulations may promote additive and/
or synergistic effects on training and/or performance.
Regulatory status
USA
The legal and regulatory status of creatine forms other than
CM in the USA, the largest market worldwide for dietary
supplements, is somewhat ambiguous. According to US
law, a “dietary supplement” is deﬁned as “…a product
(other than tobacco) intended to supplement the diet that
bears or contains one or more of the following dietary
ingredients: a vitamin; a mineral; an herb or other
botanical; an amino acid; a dietary substance for use by
man to supplement the diet by increasing the total dietary
intake; or a concentrate, metabolite, constituent, extract…”
(Federal Food, Drug and Cosmetic Act 1938a). Creatine,
an amino acid derivative, would appear to satisfy this
requirement. A “new dietary ingredient” (NDI) is deﬁned
as “…a dietary ingredient that was not marketed in the
United States before October 15, 1994…” The law con-
siders a dietary supplement that contains a new dietary
ingredient adulterated, unless the ingredient has been
present in the food supply as an article used for food in a
form in which the food has not been chemically altered, or
there is a history of safe use of the ingredient and that the
ingredient is the subject of a 75-day premarket notiﬁcation
to the Food and Drug Administration (FDA) (Federal Food,
Drug and Cosmetic Act 1938b). The requirement for the
notiﬁcation to FDA prior to entering the market is to
demonstrate to the agency that the ingredient, as intended
to be used, is reasonably expected to be safe.
The legal and regulatory status of CM is unequivocal.
CM ﬁrst appeared on the US market in 1993 (EAS 1993)
and therefore is not an NDI and instead is considered
“Grandfathered” (i.e., a dietary ingredient marketed in the
USA prior to 15 October 1994). Furthermore, it satisﬁes the
statutory requirement of having been present in the food
supply in a form that has not been chemically altered. Since
1994, many new alternate forms of creatine have entered
the US marketplace, and only several of these have been
subjected to the requisite 75-day new dietary ingredient
notiﬁcation (NDIN) to FDA. These alternate forms of
creatine include, but may not be limited to, CC, CEE, COP,
CPY, creatine malate (CML), creatine phosphate (CP),
creatine-L-carnitinate (CLC), and tricreatine orotate (TCO).
Of these, only CEE, CPY, CLC and TCO have been the
subject of an NDI to the FDA, submitted to the agency
between 1998 and 2004 (FDA 1995). The FDA has
objected to each notiﬁcation (with the exception of CPY
where no decision has yet been posted) citing one or more
of the following reasons as the basis for their objection:
1. the form(s) of creatine may not be legal dietary
ingredients as deﬁned by the FD&C Act §201(ff);
2. inadequate information to conclude that the form(s) of
creatine is reasonably expected to be safe due to
insufﬁcient safety data and/or failure to establish a
history of safe use; and/or,
3. inadequate information about the chemical identity of
the creatine form(s)
In each of its letters of objection, FDA includes the
following text: “Therefore, your product may be adulter-
ated under 21 U.S.C 342(f)(1)(B) as a dietary supplement
that contains a new dietary ingredient for which there is
inadequate information to provide reasonable assurance
that such ingredient does not present a signiﬁcant or
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a product into interstate commerce is prohibited under 21
U.S.C. 331(a) and (v)…”
Due to the nature of the notiﬁcation process in the USA,
a non-response from FDA could, in theory, be considered a
“non-objection” from the agency. Thus, the agency’s view
on the regulatory status of CPY remains unclear. However,
with the notiﬁcation process, FDA maintains the right to
object at any time, whether it has previously responded or
not. Thus, with the exception of CM and perhaps CPY,
other forms of creatine appear to be on the US market
without the proper sanction from FDA or without notiﬁ-
cation to FDA altogether.
Canada
In Canada, creatine is considered a natural health product
(NHP), the regulation of which is administered by the
Natural Health Products Directorate (NHPD) of Health
Canada (NHPD 2003). The NHP regulation requires that
all NHP products be licensed and approved by the NHPD,
and each is assigned an eight-digit numerical code. With
respect to ingredients, the NHPD has developed a com-
pendium of monographs as a tool to assist with the review
of the safety and efﬁcacy of many commonly used NHPs
(NHPD 2007). This allows applicants to reference an
NHPD monograph in support of their product license
application and circumvents the need to evaluate ingredi-
ents already known to be safe and efﬁcacious when used
under the conditions speciﬁed in the NHPD monograph.
For creatine, only CM has been approved for use in NHPs
and was recently assigned a monograph by the NHPD
(NHPD 2008). At present, there are 17 creatine-containing
licensed and approved NHPs, all of which contain CM
(NHPD 2010).
European Union
In the EU, creatine is regulated as a food supplement under
the Food Supplement Directive (FSD) (EPC 2002) and the
directive on substances that may be added for speciﬁc
nutritional purposes in foods for particular nutritional uses
(FPNU) (EPC 2001). In 2004, the European Food Safety
Authority (EFSA) issued a positive opinion on CM for
FPNU (EFSA 2004). No other opinions have been issued
on any other creatine forms, either by EFSA or its prede-
cessor (the Scientiﬁc Committee on Food, SCF).
Japan
In Japan, dietary substances are legally classiﬁed as food,
food additives, or “non-drug” (food), and are subject to one
of two regulations, both enforced by the Ministry of
Health, Labor and Welfare (MHLW). CM is categorized as
a “non-drug” (MHLW 2009) and is permitted for use as
both a food ingredient and a food additive under the Food
Sanitation Law (MHLW 2001), allowing it to be imported,
distributed, and produced as food in Japan.
New forms of creatine must be approved by the MHLW
before they can be imported, distributed, and produced in
Japan, one requirement being that sufﬁcient documentation
on the safety and similarity to CM must be provided.
Currently, two new forms of creatine, CC, and CPY have
been approved for import to Japan.
South Korea
In South Korea, the category of dietary supplements was
established through legislation in 2004 and is regulated by
the Korean Food and Drug Administration (KFDA) (Shi-
mizu 2008). New ingredients must be approved by KFDA
and are required to have sufﬁcient toxicological and human
clinical trial data supporting the safety and efﬁcacy of the
recommended daily dosage. An application for registration
of CM was ﬁled with the KFDA in 2005 and was approved
for use in dietary supplements in 2008, along with an
accompanying health claim (KFDA 2009). At present, no
other forms of creatine have been approved for use in
South Korea.
Brazil
In Brazil, nonessential nutrients (such as creatine) are reg-
ulated as bioactives or novel food ingredients and must
receive approval from the Brazilian National Sanitary Sur-
veillance Agency (or ANVISA) before entering the
marketplace (Lajolo and Miyazaki 2007) the approval is
based on a comprehensive review of the safety and efﬁcacy
of the ingredient and establishes speciﬁc requirements for
dosage and purity levels, and approved label claims, among
other important parameters. ANIVSA recently approved the
use of CM in foodstuffs for athletes (reference “Regulations
concerning foodstuffs for athletes”. Chapter III, Article 10.
The National Health Surveillance Agency Collegiate Board
of Directors. 2010). Thus far, Brazil is the only Latin
American country to approve the use of creatine and this
approval applies speciﬁcally to CM.
Analysis
The legal and regulatory status of CM is unequivocal in the
major global markets for dietary or food supplements. The
status of other creatine forms present in the marketplace
and/or subjected, in the case of the USA, to a pre-market
notiﬁcation is less clear. These alternatives to CM are
prevalent in the market, yet do not appear to have met the
Efﬁcacy and safety of novel creatine forms 1379
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countries examined. In countries where regulatory
approval is required prior to use, with the exception of
Japan (CC and CPY), none of these forms has achieved
approval. However, it is possible that at the time of this
review, additional decisions may be pending by regulatory
authorities.
In the USA, a key determinant triggering the need for an
NDIN to FDA is whether an NDI which has been present
in the food supply has been chemically altered (Federal
Food, Drug and Cosmetic Act 1938b). Chemical alteration
of an ingredient is presumed to alter its biologic behavior
and hence a separate safety assessment is required to
establish reasonable expectation of safety or that the
altered ingredient is comparable to the native ingredient in
relevant characteristics. The various forms listed in Table 2
appear to meet the criteria of being chemically altered, as
they appear to be distinct chemical entities (via covalent
bonding) versus CM, and thus all are subject to the req-
uisite premarket NDIN to FDA. Only four of the eight
forms have been subjected to such a notiﬁcation and all but
one (CPY, no decision to date) have been objected to by
FDA. In its responses, the agency has indicated that the
form of creatine may not even be a legal dietary ingredient
and/or notiﬁers have failed to establish a reasonable
expectation of safety and/or provided inadequate infor-
mation on the chemical identity of the given creatine form.
Explanations as to why these alternate creatine forms
are prevalent in the marketplace despite not having met the
legal and regulatory requirements in the various markets
are likely two-fold. Legal deﬁnitions of and regulatory
requirements for “dietary supplements” (USA and Korea),
“food supplements” (EU), “natural health products”
(Canada), and “non-drug food additives” (Japan) are
complex, differ between countries/regions, and can be
confusing. Lack of awareness and/or understanding of the
given country’s applicable requirements may be one
explanation for the lack of compliance on the part of some
marketers. To the extent that the laws and regulations are
known and understood, inadequate enforcement by regu-
lators can create an environment where noncompliance is
perceived to be without consequences, resulting in the
forgoing of required registration or notiﬁcation require-
ments. In the USA, the increased prevalence of these
alternate forms (CEE in particular) in dietary supplement
products, with no enforcement action from FDA, has
helped to support this misperception.
The public health implications of having unsanctioned
or unapproved forms of creatine on the market remain to
be fully realized. While classical animal toxicity data
(Mertschenk et al. 2001) and short- and long-term clinical
safety studies have been conducted in humans (Kreider
et al. 2003a; Schilling et al. 2001; Poortmans and Francaux
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1231999; Dalbo et al. 2008), the basic safety data on new
forms of creatine is lacking. At present, there do not appear
to be any imminent or speciﬁc safety concerns associated
with any of these alternate forms. However, this must be
monitored carefully through post-market surveillance and
published case reports. As far as the marketplace is con-
cerned, the presence of these newer and typically more
expensive forms of creatine in a multitude of consumer
products that are often marketed with misleading and/or
unsubstantiated claims of greater bioavailability, efﬁcacy,
and safety sets a negative precedent. The reality that
companies need not fulﬁll the necessary registration or
notiﬁcation requirements to satisfy regulatory authorities,
but still feel free to market their ingredients/products
without penalty establishes an “unlevel” playing ﬁeld
among competitors. This undermines any incentive to
invest upfront resources to establish ingredients as safe and
efﬁcacious prior to reaching consumers. Inevitably, this
will result in unintended and unforeseen consequences,
which will serve to erode consumer conﬁdence.
Summary
Creatine monohydrate supplementation has been consis-
tently reported in the literature to increase muscle
phosphagen levels, improve repetitive high-intensity exer-
cise performance, and promote greater training adaptations.
Moreover, it has been found to be a stable form of creatine
that is not signiﬁcantly degraded during the digestive
process and either taken up by muscle or eliminated in the
urine. No medically signiﬁcant side effects have been
reported from CM supplementation despite the widespread
worldwide use and the regulatory status of CM not being
well established. Conversely, the efﬁcacy, safety, and
regulatory status of most of the newer forms of creatine
found in dietary supplements have not been well estab-
lished. Additionally, there is little to no evidence
supporting marketing claims that these newer forms of
creatine are more stable, digested faster, and more effective
in increasing muscle creatine levels and/or associated with
fewer side effects than CM.
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